Compare Regeneron Pharmaceuticals Inc (REGN) vs Zillow Group Inc Class C (Z) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.

The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.

Zillow Group (Z) trades at $28.65, up 5.02% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported revenue of $2.58 billion in 2025, turning a net profit of $23 million after a loss in 2024, and shows improving margins. Recent news highlights AI integration in real estate and resolution of an FTC lawsuit, while the housing market faces affordability challenges.

The outlook is cautiously optimistic with a consensus price target of $60.33, implying significant upside, but risks include sensitivity to mortgage rates and competitive pressures. Earnings have beaten expectations in two of the last three quarters, supporting growth potential amid a volatile housing sector.